Since its introduction in 2009, femtosecond laser-assisted cataract surgery (FLACS) has promised to revolutionize cataract surgery. Despite its promise, the assessment of FLACS's perceived benefits has proven to be far more complicated than initially might have been thought. Most studies to date have not provided validation of FLACS technology as a clinically significant advancement on our current techniques. We review FLACS technology and outcomes, including detailed analysis of safety, efficacy, cost-effectiveness, and future prospects using data from the literature and our own published clinical experience.
T echnological innovations in surgical technique and equipment have made cataract surgery increasingly safe and more efficient over the years. One such revolutionary innovation was the introduction of lens phacoemulsification technology by Charles Kelman in 1967.
1 A full 25 years after the introduction of phacoemulsification cataract surgery (PCS) questions were still being asked about its efficacy and scientific validity.
2
McNab raised valid criticism of PCS regarding direct outcome comparison, safety, the influence of market forces, cost-effectiveness, the fairness of subjecting patients to a learning curve, and lack of scientific scrutiny. McNab stated, "if we agree that good vision, uncomplicated surgery, and patient benefits are the goals of cataract surgery, then it serves little purpose … to perform backflips off the high board just to have the chance to swim in the pool". 2 McNab's article titled "Why Phaco?" could easily have been called "Why Femto?" as today femtosecond laser-assisted cataract surgery (FLACS) is confronted with similar criticisms. Our group's contribution has sought to answer these scientifically and clinically relevant questions from a perspective independent from industry. This review will examine FLACS technology, outcomes, and applications based on current literature (which now numbers well over 500 FLACSrelated publications) from one active participant's perspective (senior author B.J.V.).
materials and methods
We conducted a PubMed search for all publications relating to FLACS using the search term "femtosecond cataract surgery". We did not use any date restrictions in the search. We last searched PubMed in April 2017. Of the initial 584 articles found, 144 were considered relevant for the purposes of this review after careful study of all titles and abstracts. The authors then rated these according to relevance, scientific merit, and introduction of new knowledge, with particular focus on those articles providing direct comparison between FLACS and PCS [especially randomized controlled trials (RCTs), paired eye studies, and comparative cohort studies]. Ultimately, 98 articles considered by the authors most relevant to this review have been included.
resUlts

Promises of FlaCs
Femtosecond laser systems have been in use since 2001 for creation of corneal flaps in laser refractive surgery. The systems use ultra-short pulses of laser, capable of photodisrupting tissues at a preset depth; photodisruption produces microcavitation bubbles, the expansion of which form a resection plane. The ability of femtosecond laser to deliver safe, precise, and reproducible corneal flaps is well documented. 3, 4 In an attempt to improve the precision and safety of cataract surgery, in 2009, Nagy and colleagues 5 proposed a novel technique to perform key steps of cataract surgery including corneal incisions, anterior capsulotomy, and lens fragmentation using an intraocular femtosecond laser. Femtosecond laser-assisted cataract surgery promised the theoretical benefits of more precise surgical incisions, greater reproducibility of surgery, and increased safety, both in terms of successful uniform capsulotomies with better intraocular lens (IOL) centration and decreased collateral damage to the cornea and the posterior capsule.
5-8 safety
The first femtosecond laser system commercially available for use in cataract surgery was the LenSx system (LenSx Lasers Inc, Aliso Viejo, CA; later acquired by Alcon Inc, Houston, TX). The technology became poised to revolutionize the world of cataract surgery and caught the interest of many early adopters.
9,12-14
The problem with the initial LenSx curved hard contact lens patient interface was that pressing the cornea against a rigid surface caused deformation of the cornea and attendant corneal folds. These corneal folds were found to be associated with high rates of incomplete capsulotomy and the higher suction pressure for the interface associated with higher intraocular pressure (IOP) rise.
9 Fortunately, the LenSx docking system was upgraded with a soft contact lens interface (SoftFit) which proved a significant improvement, with corresponding reduction in complication rates to more acceptable levels. 15, 16 Concurrent progress on other platforms meant that subsequently, several other femtosecond laser platforms for cataract surgery became commercially available: the Catalys precision laser system (OptiMedica Inc, Sunnyvale, CA; later acquired by Abbott Medical Inc, Abbott Park, IL), the Lensar system (Lensar Inc, Orlando, FL), the Victus system (Bausch + Lomb Inc, Garden City, NY), and the Femto LDV Z8 (Ziemer Inc, Brügg, Switzerland), with the latter 2 capable of performing both cataract and corneal procedures on a single platform. Technical comparisons of these different operating systems can be found elsewhere in the literature.
17-19
Ethically, clinicians need to ensure they are providing the best for their patients and have a sound rationale for the advice they provide in comprehensive terms of safety, outcomes, and cost.
20 Though the potential of femtosecond laser technology seemed exciting, for many clinicians concern existed to ensure the scientific validation to which McNab had referred. Given the widespread commercial availability of femtosecond laser systems, it is reasonable for clinicians to expect that both the technology and the systems are determined efficacious by various regulatory bodies (such as the Therapeutic Goods Administration in Australia). Ironically (for both scientists and regulators), more than 5 years into commercial availability of FLACS, the results of well-designed RCTs remain outstanding. Loose use of language in terms of safety has permeated both our scientific literature and, more importantly, our discussions with patients. At the time of our group's first involvement with FLACS in 2012, there remained valid questions about the efficacy of FLACS and its relative safety profile compared with the very safe and wellestablished PCS.
Recognizing the paucity of good comparative studies, our group embarked on an assessment of FLACS technology utilizing the Catalys femtosecond laser delivery system. We considered that a consecutive patient (without exclusion) comparative cohort study offered the most appropriate (real-world) approach to provide evidence to guide our practice. By way of providing structure to this literature review, we will highlight the results of our group's publications that represented the first published prospective comparative cohort studies designed specifically to explore matters such as the effect of FLACS on IOP/glaucoma patients, capsular integrity, postoperative inflammation, corneal stress including endothelial stress, operative outcomes, visual outcomes, and cost-effectiveness.
21-35
It is relevant to note that our real-world study approach involved what we termed clinicosocioeconomic case selection. We first determined if any contraindications to FLACS existed as per manufacturer guidelines (approximately 5% of patients; eg, corneal opacity). These patients were not excluded but became part of the PCS cohort. All remaining patients then self-selected into either FLACS or PCS based on their socioeconomic circumstances (ability to afford the $750 additional fee for FLACS) after being offered the option of FLACS based on its theoretical clinical benefits.
Intraocular Pressure During Femtosecond Laser Pretreatment
Femtosecond laser-assisted cataract surgery requires the application of suction to stabilize the eye before corneal incisions, anterior capsulotomy, and lens fragmentation are performed utilizing the femtosecond laser delivery system. As transient IOP rises of greater than 90 mm Hg have been demonstrated in laser in situ keratomileusis (LASIK) patients after the application of vacuum, 36, 37 it was important to determine the magnitude of IOP rise associated with FLACS. Although uncommon, sudden and dramatic IOP changes may cause vascular and rhegmatogenous complications.
38-41 A mean IOP rise of 12-25 mm Hg from baseline is demonstrated in patients undergoing femtosecond laser pretreatment using liquid optic interface. 29, 32, 42, 43 The rise in IOP persists after removal of the docking suction to above baseline levels by a mean of 8-9 mm Hg but returns to baseline after several hours. 29, 32, 42 In contrast to LASIK, the IOP rise associated with FLACS is small and seems to be well tolerated in healthy eyes.
32
No association between IOP rise and the number of docking attempts, vacuum time, treatment time, or central corneal thickness was established.
Some systems utilize nonapplanating liquid interface docking systems, whereas others maintain more direct applanating docking contact with the treated eye. The IOP rise associated with direct contact applanation interfaces is reported to be significantly higher, 44 although this has been addressed through newer soft contact interfaces (such as SoftFit).
IOP Comparison of Glaucomatous vs Nonglaucomatous Eyes
Although fluctuations in IOP are generally well tolerated in healthy eyes, cataract patients are often older and have additional comorbidities such as glaucoma that may place them at higher risk for complications.
17 A significant increase in IOP during FLACS could result in nerve fiber damage and glaucoma progression. The rise in IOP during and after femtosecond laser treatment is 2-3 mm Hg greater in glaucomatous eyes (primary open angle glaucoma) than in healthy eyes. 29 There is no association between glaucoma severity and IOP rise in FLACS. 29 This rise in IOP is well tolerated in the short term 29 ; however, long-term implications for eyes with glaucoma remain unknown. Furthermore, the uncertain influence of FLACS suction on the stability of thin avascular cystic blebs highlights that some posttrabeculectomy candidates for FLACS might, in our opinion, present a relative contraindication to this procedure and surgeons should proceed with caution.
Effective Phacoemulsification Time
Conventional PCS uses ultrasound energy to emulsify the lens before removal. Ultrasound energy within the eye has the potential to damage surrounding structures and has been implicated in the pathogenesis of corneal endothelial cell loss, wound burn, and cystoid macular edema (CME) along with postoperative inflammation.
FLACS studies is reduced effective phacoemulsification time (EPT). 11, 47, 48 The range in reduction depends on many factors such as lens grade, preferred technique during nuclear disassembly (eg, chop vs divide and conquer), and the degree to which FLACS segments/fragments the lens. Utilizing Pentacam's lens densitometry program to obtain Pentacam nucleus staging (PNS) provides an objective measure of nuclear density and correlates well with established Lens Opacities Classification System (LOCS) 49 grading, and in our own study 26 the eyes were well matched for baseline characteristics, including patient demographics and cataract grading. We found EPT was reduced by 84% in the femtosecond laser pretreatment group. After optimization of FLACS with fragmentation grid size and phacoemulsification tip we observed an overall reduction in mean EPT of 96%, with 45 cases (30%) achieving zero EPT. In our experience, using full fragmentation FLACS patterns means most LOCS 2 and below (PNS 2.5) can be removed without any additional phacoemulsification energy (zero phaco). The ability to perform cataract surgery with zero EPT certainly remains an attractive future target for FLACS and, provided it can achieve this consistently in all cases, has the potential to eliminate the requirement for phacoemulsification from our procedures. Until that time, though, we will continue to require a fully capable phacoemulsification surgery system in addition to FLACS. This continues to jeopardize any future cost-effectiveness that FLACS might realize. Cost-effectiveness analysis was clearly warranted and is further discussed below.
Effect of FLACS on Corneal Endothelium
Reduced phacoemulsification energy during standard PCS is associated with reduced postoperative corneal edema and endothelial cell loss. 50, 51 In our prospective comparative cohort study we demonstrated a significant early reduction in postoperative corneal edema and endothelial cell loss in the FLACS cohort compared with PCS; however, by 6 months postoperatively no difference between the 2 groups could be demonstrated. 25 That is, mean endothelial cell loss between FLACS and PCS was similar. This was puzzling given the early postoperative benefits, so we analyzed subset groups further. We found FLACS cases that had undergone manual corneal incisions performed better than the PCS group, with those achieving zero phaco performing the best. However, the subgroup of patients who received laser-automated corneal incisions (FLACS incisions) had greater endothelial cell loss at 6 months than all other eyes. Laser-automated corneal incisions seemed to adversely affect the corneal endothelial cells in our study population. Cellular inflammation and apoptosis seems to be closely linked with femtosecond laser energy used, with higher µJ settings associated with higher percentage of inflammatory and apoptotic cells. 52, 53 Our results are consistent with other groups, which show upregulated apoptosis after FLACS, and in vitro studies indicating an upregulated postoperative corneal wound healing response to FLACS.
54
If the only consistently established benefit of FLACS is in reducing EPT (segmentation and fragmentation) and protection of the corneal endothelium (the most clinically relevant benefit of reduced EPT), then performing corneal incisions by FLACS seems to negate this corneal benefit and may in fact be detrimental (as evidenced in our cohort). Furthermore, not infrequently, incision location by FLACS proved less than ideal (too central) or of poor quality (incomplete) because of various factors influencing landmark recognition in the image guidance software, such as arcus senilus and unusual cornea anatomy. For this reason, our group has not performed corneal incisions using FLACS since 2014.
Early postoperative benefits to corneal thickness, volume, and volume stress index after FLACS were also not maintained at 6 months postoperative follow-up. 25 In our experience these early corneal benefits provide no functionally noticeable benefit to patients in either faster or better recovery after surgery or through better visual outcomes.
Postoperative Ocular Inflammation and Cystoid Macular Edema
Several studies have shown increased inflammatory cytokines, including prostaglandin E2 and interleukins ß and 6, in aqueous after femtosecond pretreatment.
55-57 Anterior capsulotomy, lens fragmentation time, and corneal incisions are likely the main triggers for release of inflammatory cytokines, in particular capsulotomy. 55 As in many areas of surgical analysis there are complex interplays of factors leading to these biochemical responses. Unless all of these factors are controlled for similarly, then comparisons of differing results between studies may have limitations. As with the radial tear safety signal, our group flagged a possible safety signal of raised postoperative CME in FLACS patients compared with PCS. Notably, all patients in our cohorts were pretreated with topical nonsteroidal anti-inflammatory drugs (NSAIDs) and continued both topical steroids and NSAIDs postoperatively. 57, 58 Our study looked at cases of clinical (vision affected) CME. It is important to distinguish between purely asymptomatic thickening on optical coherence tomography and clinical CME. We identified 7 cases of postoperative CME (0.8%) in the FLACS group compared with 1 case (0.2%) in the PCS group. 31 This numerical difference toward greater CME in the FLACS group was found to be weakly statistically significant, and we postulated a possible subthreshold laser effect on the retina. 31 One valid argument regarding FLACS is that we are just substituting one form of energy (ultrasound) for another (photodisruption), each of which may have sequelae. However, several other large-scale studies, including the recently published Cochrane systematic review 59 and the European Registry of Quality Outcomes in Cataract and Refractive Surgery (EUREQUO) study, 60 have failed to establish a link between FLACS and CME either due to lack of specific data or inconclusive evidence.
Our own findings have shown FLACS significantly reduced early postoperative inflammation (as measured by flare) when compared with PCS, and this seemed to be due to reduction in effective phacoemulsification time. 21 Administration of topical NSAIDs before FLACS has been also shown to reduce postoperative inflammation, with the additional potential of limiting intraoperative laser-induced miosis. 21, 57, 58 The clinical relevance is that pretreatment with topical NSAIDs may mask any significant differences in inflammation that might exist between FLACS and PCS. Nonetheless, postoperative inflammation remains an area of interest in ongoing research of FLACS compared with PCS.
curvilinear capsulorrhexis (CCC).
61-64 Precise, circular, and reproducible capsulotomy was theoretically postulated to improve effective lens position, provide better capsule overlap for the intraocular lens, and therefore reduce lens decentration and tilt and posterior capsule opacity (PCO). Each of these are explored in later sections.
Although there is no argument about the precision, circularity, and reproducibility of FLACS capsulotomies, the biomechanical strength of femtosecond laser-created capsulotomies has certainly been more open to question. The initial clinical evaluation of femtosecond capsulotomy strength and integrity were carried out in ex vivo porcine eyes. Using porcine models to test the strength and integrity of femtosecond laser-created capsulotomy has limited validity owing to the biomechanical differences in thickness and elasticity of these eyes. 65, 66 Despite the introductory claims of perfect capsulotomy with smooth edges and superior tensile strength, 5 multiple independent studies using high definition electron microscopy and finite-element modelling based on 3-dimensional atomic force microscopy have demonstrated ragged edges with microscopic postage stamp-like perforations and aberrant pits (10-100 µm from the capsule edge) on FLACS specimens in human eyes (Fig. 1) .
23,67-69 These ultrastructural features, resembling that of the can opener technique at microscopic level, suggested a plausible root-cause biomechanical basis for weakened capsular integrity and risk of radial tears.
Our own clinical experience certainly suggested such a clinicopathological correlation with fixational eye movements during capsulotomy a likely contributor to a significantly increased rate of capsular tags and tears. In our large prospective multicenter comparative cohort study of 1626 patients, there was a significantly increased rate of anterior capsule tears in the FLACS group [15/804 (1.87%)] when compared with manual CCC [1/822 (0.12%); P = 0.0002]. 22 Although the intrinsic biomechanical weakness of femtosecond laser capsulotomy exists, technology evolution, software updates, faster treatment time, and adapted laser settings such as greater vertical spot spacing and lower pulse energy levels has seen its significance diminishing to be comparable with contemporaneously published manual CCC radial tear rates. 64, 70, 71 A study by Day et al 72 from Moorfields Eye Hospital reported the incidence of anterior capsule tear at 0.1% (1/1000) in 1000 consecutive cases, highlighting that technology improvements have made significant progress in reducing the significance of this unwanted complication. Furthermore, surgical intraoperative adaptive responses have been developed, such as dimple down technique 73 and careful inspection of the capsulotomy margin before removal, allowing completion in our familiar CCC fashion.
74,75
Posterior Capsule Opacity
The jury remains out on PCO, with high rates of early postoperative PCO reported in the literature. 60, 76 These contrast Nagy's earlier publication 77 with less PCO finding postulated due to better IOL overlap and effective lens position.
FLACS in Complex Cases
Grewal et al, 19 as part of their review, highlight FLACS use in complex cases such as subluxated cataracts, corneal scar cases, after penetrating keratoplasty, pediatric cataracts, intumescent and brunescent cataracts, eyes with previous surgery, and premium IOLs cases. These uses have certainly broadened our case selection scope. 78, 79 Notwithstanding billing idiosyncrasies in different health systems, one correlation with these expanded indications has been the sensible suggestion by Dick et al 80 to co-locate the femtosecond laser platform in the operating theater. Small pupil cases can have pupil enlarging devices inserted before proceeding with FLACS intraoperatively rather than as a pretreatment.
78
Pediatric cataract cases are known to be more difficult, with lens capsules that are significantly more elastic with different biomechanical properties to adult capsules. Dick et al 79 first report the use of FLACS in a pediatric population in 2013. As we noted at the time, it was concerning that the authors reported the use of a secondary procedure (lateral canthotomy) to allow docking of the liquid optic interface, with anecdotal evidence of a similar practice by others for small palpebral fissure eyes (eg, Asian eyes). Concurrent canthotomy brings additional risks, 24 including the potential (particularly in adults) of more than 5-fold increased risk of endophthalmitis with concurrent lid surgery in cataract patients, 81 and the lifelong implications of canthotomy in the pediatric setting are unclear. Consequently, another important related consideration, as raised by McNab, 2 that we must a B determine as a scientific community is, to what extent we should be "experimenting" on our patients to achieve the ability to perform a surgical procedure of as yet unproven clinical benefit. Though clearly an argument may exist to facilitate FLACS in these more complex cases, should this extend to performing additional procedures such as lateral canthotomy, whether in the pediatric or adult setting? With the development soon after of a smaller liquid optics interface (LOI) to facilitate better docking in these cases without canthotomy, one wonders about the urgency to proceed with FLACS instead of waiting for the arrival of appropriate technology to address the secondary problem (such as smaller LOI/docking interface). These ethical dilemmas warrant better consideration in our peer-review processes, particularly when the evidence for the primary procedure (FLACS) remains debated in adults.
Other Aspects of Surgical Outcomes and Safety
Our own large prospective comparative cohort study investigated the intraoperative complications and safety of 1852 FLACS cases compared with 2228 conventional PCS cases in over 4000 consecutive operations. 22 The baseline characteristics including patient demographics, ocular comorbidities, and PNS cataract grading were well matched between the 2 groups. Incomplete capsulotomy was observed in 21 cases (1.13%), and anterior capsulotomy tag was identified in 30 cases (1.6%) of FLACS compared with 1 PCS case (0.004%). Anterior radial and posterior capsule tear were observed in 34 (1.84%) and 8 (0.43%) cases of FLACS compared with 5 (0.22%) and 4 (0.18%) cases in the PCS group, respectively. The influence of FLACS on posterior capsular tear rates remains to be clarified; however, one meta-analaysis did suggest higher rates of PC tear after FLACS.
82
Intraoperative corneal haze and pupil instability were significantly higher in FLACS with 12 (0.65%) and 30 (1.65%) cases, respectively, compared with 1 (0.04%) and 14 (0.65%) in the PCS group. Pupil size reduction after femtosecond treatment has been confirmed by others and is significantly correlated with femtosecond lens fragmentation and primary corneal incision treatment duration. 22, 83 A possible role for FLACS in resident training has been identified, 84 yet inexperience also continues to be used to validate higher complications seen in FLACS series 85 ; such contrasting positions are incongruous. In our center, though exposure to FLACS cases is provided to residents, it is our opinion that FLACS should not supplant core PCS skill development, in particular CCC.
Another relevant practical problem with widespread adoption of FLACS in the real world (including as a possible future alternate to PCS) is the small percentage of patients where FLACS was either unable to proceed or needed to be abandoned [docking failure, anxiety, mechanical positioning difficulties (eg, kyphosis)]. Additionally, relative or absolute contraindications to FLACS mean up to 5% of patients are excluded from FLACS, especially those with small pupils, corneal scarring, and docking failure.
19,85
efficacy
Visual Outcomes
Of all its promises, ultimately the promise of improved visual outcomes with FLACS 5 remains the most important test of its success when compared with PCS results. Postulated mechanisms of FLACS to improve visual outcomes compared with PCS include better capsulotomy position, lens centration, reduced phacoemulsification collateral damage, and reduced postoperative inflammatory response/faster healing. Our prospective multicenter comparative case series of almost 1000 FLACS compared with 900 PCS eyes did not demonstrate any clinically meaningful improvement in visual outcomes for FLACS. 30 Similarly, EUREQUO recently published the results of a matched casecontrol study of FLACS versus conventional CCC and phacoemulsification cataract surgery from their extensive multicenter database. 60 The study matched 2814 FLACS cases with 4987 conventional PCS cases and found the overall rate of complications higher in the femtosecond group than the PCS group. The authors concluded FLACS "did not yield better visual or refractive outcomes than conventional phacoemulsification surgery", and in fact corrected distance visual acuity was worse in the FLACS group. These findings are consistent with other studies across a range of cataract grades. 85, 86 A number of papers have suggested potential visual benefit of FLACS in specific patient subsets (eg, "premium" toric and multifocal lenses).
87,88 Many of these papers are limited by design (especially small numbers and follow-up). Our own study of toric IOL outcomes did not reveal any additional benefit for patients undergoing FLACS procedures.
35
It is interesting how enthusiastic the uptake for FLACS astigmatic corneal relaxing incisions was long before any nomogram specific to FLACS became available, 89 with published long-term outcomes still awaited. Although FLACS does offer the possibility for performing corneal relaxing incisions for astigmatism, most surgeons would agree that toric IOLs offer a more predictable method of correcting astigmatism, but FLACS becomes another option available for specific patients.
Effective Lens Position
Though some papers have supported reduced IOL tilt and aberrations, 90-92 thus far a strong argument for improved effective lens position after FLACS is lacking. 61 However, reaffirming the residual potential of FLACS systems to deliver outcome gains through effective lens position is the ability with some platforms to revisit femtosecond laser after removal of nuclear and cortical material and perform a precise posterior capsulotomy opening.
93
As such, the theoretical effective lens position benefit of FLACS technology may yet be realized through integration with IOL designs that take advantage of anterior ± posterior capsulotomy, such as bag-in-the-lens, 94 and newer IOLs with flange design, such as Masket ND IOL Type 90S (Morcher GmbH, Stuttgart, Germany). Other relevant research to pieces in the effective lens position story include consideration of optimal capsulotomy size when performed by FLACS, 95, 96 particularly when capsulotomy size may be relevant to capsule biomechanics.
Cost-effectiveness
It is possible that femtosecond technology will offer an incremental benefit over standard PCS, particularly in higher risk patients such as very dense cataracts or those with significantly reduced endothelial cell count. However, any recommendation for its use in everyday practice is hindered by the lack of quality data demonstrating clinically relevant safety or visual outcome effectiveness, along with the low cost-effectiveness of the technology. In 2016, a systematic Cochrane review was published of all available RCTs comparing FLACS with conventional PCS.
59
A total of 16 RCTs with 1638 eyes of 1245 adult participants from 6 countries were included in the review. In their quest to compare the effectiveness of FLACS with standard PCS the authors concluded "the evidence…could not determine the equivalence or superiority of laser-assisted cataract surgery compared to standard manual phacoemulsification [bold and italics added]" in all of the review's outcome measures (including visual outcomes).
Our own cost-effectiveness analysis 28 applied econometric modelling based on a hypothetical cohort of patients undergoing FLACS versus PCS, providing very generous assumptions in favor of FLACS in both safety and visual outcomes. It found at current costs to patients FLACS was not even close to achieving any incremental cost-effectiveness ratio (ICER) benefit. Our analysis indicated that with even a perfect safety record or a modest 5% improvement in visual acuity outcomes, FLACS would not achieve a favorable ICER, yielding a quality gain of only 0.06 years (or 3 weeks) at best.
Future Prospects
Two well designed RCTs (FEMCAT and FACT) are currently investigating the long-term visual outcomes, complications, safety, and effectiveness of this technology compared with standard PCS. 97, 98 Although the application of these studies in the real world is limited by their inherent exclusions, the results of these studies should at least shed light on further utility (ICER) of femtosecond technology in cataract surgery for the majority of our patients.
The future of FLACS remains uncertain. If current noninferiority studies prove it to be noninferior to PCS then, as McNab suggested, there is little benefit in performing a "back flip off the high board" and it would be hard to justify the high cost of FLACS to our patients and the health system. It remains possible, however, that other technologies, such as specifically suited IOL platforms, may revive the enthusiasm for FLACS seen by early adopters among the broader surgical community. Interestingly, in most countries where FLACS is available, its market share has not grown significantly.
In some respects, it is unfortunate that the FLACS landscape evolved the way it did. If the various early high complication rates, learning curve issues, and technology "upgrades" had occurred before commercial availability, the conversation now might be different. Failure in the progress of FLACS technology rests squarely in the hands of the companies who seem to have placed short-term returns above long-term viability of their products.
ConClUsions
There remain some concluding questions: Does the reduction in EPT provide anything of substance in regard to clinically relevant benefit to corneal endothelium? Given the possible detrimental impact of utilizing FLACS for corneal incisions, should we still be utilizing these? How far should we go as clinicians in supporting a technology that remains significantly overpriced in the hope of its eventual cost-effectiveness and therefore utility? And finally, should we be still offering FLACS?
At present, there is no clinical evidence that even the most at-risk group for corneal decompensation (eg, Fuchs endothelial 1.
2.
3.
4.
dystrophy) derives any benefit from FLACS. Ultimately, for individual patients there may be benefit (real or perceived) and patients need to make an informed decision that best serves their needs. Correlated with a surgeon's assessment of "perceived" benefit for their patients will be each surgeon's surgical ability in utilizing FLACS versus PCS. Some surgeons' surgical outcomes will be improved, others not. Ultimately, one thing standardized surgery would bring is regression to the mean. But is regression to the mean a good thing?
Though our group remains enthusiastic for new technology like FLACS, our clinical indications for FLACS have become quite narrow: now less than 5% of all cases, including those with very mature cataract (especially with compromised zonules) or those with significant corneal endothelial compromise. Even these select patient groups have only theoretical clinical benefits. For the remaining patients (the majority), in our opinion FLACS does not provide either sufficient clinical benefit or cost-effectiveness to warrant its use.
